IMM Immupharma Plc

TIDMIMM

RNS Number : 8788S

Immupharma PLC

28 June 2018

28 JUNE 2018

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

2018 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

-Ends-

 
 For further information please contact: 
                                                      + 44 (0) 20 
  ImmuPharma PLC (www.immupharma.co.uk)                7152 4080 
  Tim McCarthy, Chairman 
  Lisa Baderoon, Head of Investor Relations           + 44 (0) 7721 
   Twitter: @immupharma                                413496 
 
  Northland Capital Partners Limited (NOMAD & 
   Joint Broker) 
   David Hignell, Dugald Carlean, Jamie Spotswood, 
   Corporate Finance                                  +44 (0)20 3861 
   Rob Rees, Corporate Broking                         6625 
  Bryan, Garnier & Co. (Joint Broker) 
   Phil Walker, Corporate Finance                     +44 (0)20 7332 
   Dominic Wilson, Sales                               2500 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGFMGZVNRLGRZG

(END) Dow Jones Newswires

June 28, 2018 07:16 ET (11:16 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024